These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21286026)

  • 41. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis.
    Liu TJ; Lam JP
    Am J Health Syst Pharm; 2012 Jul; 69(13):1109. PubMed ID: 22722588
    [No Abstract]   [Full Text] [Related]  

  • 42. Electrolytes imbalance: a rare side effect of piperacillin/ tazobactam therapy.
    Hussain S; Syed S; Baloch K
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):419-20. PubMed ID: 20642978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population.
    Pratt JA; Stricherz MK; Verghese PS; Burke MJ
    Pediatr Blood Cancer; 2014 Feb; 61(2):366-8. PubMed ID: 24038944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Piperacillin/tazobactam--induced petechial rash.
    Abate G; Godbole K; Springston C
    Ann Pharmacother; 2010; 44(7-8):1345-6. PubMed ID: 20571103
    [No Abstract]   [Full Text] [Related]  

  • 46. Piperacillin/tazobactam induced thrombocytopaenia--a delayed response.
    Macwilliam JL; Mistry R; Floyd MS; Baird AD
    BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22778457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
    Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
    Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
    Watkins RR; Deresinski S
    Clin Infect Dis; 2017 Nov; 65(12):2137-2143. PubMed ID: 29020249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
    Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
    Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
    Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymphocyte transformation tests predict delayed-type allergy to piperacillin/tazobactam in patients with cystic fibrosis.
    Roehmel JF; Rohrbach A; Staab D; Mall MA; Ogese M; Doerfler F; Naisbitt D
    J Cyst Fibros; 2024 May; 23(3):573-578. PubMed ID: 38087680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis.
    Behbahani R; Kostman JR
    Ann Pharmacother; 1995 Sep; 29(9):936-7. PubMed ID: 8547747
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
    Siami G; Christou N; Eiseman I; Tack KJ;
    Antimicrob Agents Chemother; 2001 Feb; 45(2):525-31. PubMed ID: 11158750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy.
    Gerber L; Wing EJ
    Clin Infect Dis; 1995 Oct; 21(4):1047-8. PubMed ID: 8645807
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.